

### Remarks

In response to the written restriction, applicants hereby elect Group XI (i.e., claims 120-137) with traverse. Applicants submit that there is no need for such a written restriction requirement in view of their filing a Preliminary Amendment on September 26, 2001, which canceled claims 1-119 and 138-147. A copy of that Preliminary Amendment is attached.

As far as the election of species requirement is concerned, applicants hereby make the following election with traverse: (1) the type of solid support is glass; (2) the form of solid support is a slide; (3) the group used to functionalize the solid support is a carboxyl group; and (4) the specific capture ligand is an oligonucleotide having a nucleotide sequence complementary to SEQ ID NO: 2. The reason for this traversal is that all species of the elected invention are closely related and require common areas of search and consideration. Accordingly, no benefit is derived by maintaining the election of species.

Finally, claim 120 has been amended to require the limitation "wherein each oligonucleotide probe of the array differs from its adjacent oligonucleotide probe by at least 25% of the nucleotides." Support for this limitation is found in original claim 81.

Respectfully submitted,

Date: November 3, 2003



Michael L. Goldman  
Registration No. 30,727

NIXON PEABODY LLP  
Clinton Square, P.O. Box 31051  
Rochester, New York 14603-1051  
Telephone: (585) 263-1304  
Facsimile: (585) 263-1600

Certificate of Mailing - 37 CFR 1.8(a)	
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450, on the date below.	
Date 11/3/03	Wendy L. Barry

PATENT  
Docket No.: 19603/3356 (CRF D-1595F)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) :	Barany et al.	)	Examiner:
		)	To Be Assigned
Serial No. :	To Be Assigned	)	
		)	Art Unit:
Cnfrm. No. :	To Be Assigned	)	To Be Assigned
		)	
Filed :	Herewith	)	
		)	
For :	DETECTION OF NUCLEIC ACID SEQUENCE	)	
	DIFFERENCES USING THE LIGASE	)	
	DETECTION REACTION WITH	)	
	ADDRESSABLE ARRAYS	)	

---

PRELIMINARY AMENDMENT

Commissioner for Patents  
Washington, D.C. 20231  
Box: Patent Application

Dear Sir:

Please amend the above-identified patent application as follows:

In the Specification:

Please substitute the pending paragraphs at page 1, lines 4-5, page 17, lines 9-29, page 40, lines 14-34, page 42, lines 17-25, page 42, lines 27-33, page 43, lines 1-7, and page 55, lines 9-24 with the amended paragraphs at page 17, lines 9-29, page 40, lines 14-34, page 42, lines 17-25, page 42, lines 27-33, page 43, lines 1-7, and page 55, lines 9-24 as follows:

At page 1, lines 4-5:

This application is a divisional of U.S. Patent Application Serial No. 08/794,851, filed February 4, 1997, which claims the benefit of U.S. Provisional Patent Application Serial No. 60/011,359, filed February 9, 1996.

At page 17, lines 9-29:

Figure 6 is a flow diagram of a PCR/LDR process, in accordance with the present invention, where insertions (top left set of probes) and deletions (bottom right set of probes) are distinguished. On the left, the normal sequence contains 5 A's in a polyA tract. The mutant sequence has an additional 2As inserted into the tract. Therefore, the LDR products with addressable array-specific portions Z1 (representing the normal sequence) and Z3 (representing a 2 base pair insertion) would be fluorescently labeled by ligation to the common primer. While the LDR process (e.g., using a thermostable ligase enzyme) has no difficulty distinguishing single base insertions or deletions in mononucleotide repeats, allele-specific PCR is unable to distinguish such differences, because the 3' base remains the same for both alleles. On the right, the normal sequence is a (CA)<sub>5</sub> repeat (i.e. CACACACACA (SEQ. ID. No. 1)). The mutant contains two less CA bases than the normal sequence (i.e. CACACA). These would be detected as fluorescent LDR products at the addressable array-specific portions Z8 (representing the normal sequence) and Z6 (representing the 2 CA deletion) addresses. The resistance of various infectious agents to drugs can also be determined using the present invention. In Figure 6, the presence of ligated product sequences, as indicated by fluorescent label F, at the address having capture oligonucleotides complementary to Z1 and Z3 demonstrates the presence of both the normal and mutant poly A sequences. Similarly, the presence of ligated product sequences, as indicated by fluorescent label F, at the address having capture oligonucleotides complementary to Z6 and Z8 demonstrates the presence of both the normal CA repeat and a sequence with one repeat unit deleted.

At page 40, lines 14-34:

To illustrate the concept, a subset of six of the 36 tetramer sequences were used to construct arrays: 1 = TGCG; 2 = ATCG; 3 = CAGC; 4 = GGTA; 5 = GACC; and 6 = ACCT. This unique set of tetramers can be used as design modules for the required 24-mer addressable array-specific portion and 24-mer complementary capture oligonucleotide address sequences. This embodiment involves synthesis of five addressable array-specific portion (sequences listed in Table 2). Note that the numbering scheme for tetramers allows abbreviation of each portion (referred to as "Zip #") as a string of six numbers (referred to as "zip code").

**Table 2. List of all 5 DNA/PNA oligonucleotide address sequences.**

Zip #	Zip code	Sequence (5' → 3' or NH <sub>2</sub> → COOH)	G+C
Zip11	1-4-3-6-6-1	TGCG-GGTA-CAGC-ACCT-ACCT-TGCG (SEQ. ID. No. 2)	15
Zip12	2-4-4-6-1-1	ATCG-GGTA-GGTA-ACCT-TGCG-TGCG (SEQ. ID. No. 3)	14
Zip13	3-4-5-6-2-1	CAGC-GGTA-GACC-ACCT-ATCG-TGCG (SEQ. ID. No. 4)	15
Zip14	4-4-6-6-3-1	GGTA-GGTA-ACCT-ACCT-CAGC-TGCG (SEQ. ID. No. 5)	14
Zip15	5-4-1-6-4-1	GACC-GGTA-TGCG-ACCT-GGTA-TGCG (SEQ. ID. No. 6)	15

Each of these oligomers contains a hexaethylene oxide linker arm on their 5' termini [P. Grossman, et al., Nucl. Acids Res., 22:4527-4534 (1994), which is hereby incorporated by reference], and ultimate amino-functions suitable for attachment onto the surfaces of glass slides, or alternative materials. Conjugation methods will depend on the free surface functional groups [Y. Zhang, et al., Nucleic Acids Res., 19:3929-3933 (1991) and Z. Guo, et al., Nucleic Acids Res., 34:5456-5465 (1994), which are hereby incorporated by reference].

At page 42, lines 17-25:

This concept is illustrated below using the two addresses, Zip 12 and Zip 14. These two addresses are the most related among the 25 addresses schematically represented in Figures 18 and 20 (discussed *infra*). These two addresses have in common tetramers on every alternating position (shown as underlined):

Zip 12 (2-4-4-6-1-1) = 24 mer

5' - ATCG GGTA GGTA ACCT TGCG TGCG-3' (SEQ. ID. No. 7)

Zip 14 (4-4-6-6-3-1) = 24 mer

5' - GGTA GGTA ACCT ACCT CAGC TGCG-3' (SEQ. ID. No. 8)

At page 42, lines 27-33:

In addition, they have in common a string of 12 nucleotides, as well as the last four in common (shown as underlined):

Zip 12 (2-4-4-6-1-1) = 24 mer

5' - ATCG GGTA GGTA ACCT TGCG TGCG-3' (SEQ. ID. No. 9)

Zip 14 (4-4-6-6-3-1) = 24 mer

5' - GGTA GGTA ACCT ACCT CAGC TGCG-3' (SEQ. ID. No. 10)

At page 43, lines 1-7:

Furthermore, for other capture oligonucleotides, such as Zip 3, the number of shared nucleotides is much lower (shown as underlined):

Zip 12 (2-4-4-6-1-1) = 24 mer

5' - ATCG GGTA GGTA ACCT TGCG TGCG-3' (SEQ. ID. No. 11)

Zip 3 (3-6-5-2-2-3) = 24 mer

5' - CAGC ACCT GACC ATCG ATCG CAGC-3' (SEQ. ID. No. 12)

At page 55, lines 9-24:

Typically, 10 pmol of each of the oligonucleotides comp 12 and comp 14 (see Table 3) were 5' end labeled in a volume of 20  $\mu$ l containing 10 units of T4 polynucleotide kinase (New England Biolabs, Beverly, MA), 2.22 MBq (60  $\mu$ Ci) [ $\gamma$ - $^{32}$ P] ATP, 50 mM Tris-HCl, pH 8, 10 mM MgCl<sub>2</sub>, 1 mM EDTA, and 10 mM dithiothreitol, according to a slightly modified standard procedure described in the literature. Unincorporated radioactive nucleotides were removed by filtration over a column containing superfine DNA grade Sephadex G-25 (Pharmacia, Piscataway, NJ). The Sephadex was preswollen overnight at 4 °C in 10 mM ammonium acetate. The labeled oligonucleotide probes were dried in vacuum and dissolved in hybridization solution (0.5 M Na<sub>2</sub>HPO<sub>4</sub> [pH 7.2], 1% crystalline grade BSA, 1 mM EDTA, 7% SDS). The specific activity of the labeled oligonucleotide probes comp 12 and comp 14 was  $2.86 \times 10^6$  cpm/pmol and  $2.43 \times 10^6$  cpm/pmol, respectively.

**Table 3. Oligonucleotides used (5' to 3')**

12	Aminolink- spacer 18- ATC GGG TAG GTA ACC TTG CGT GCG (SEQ. ID. No. 13)
14	Aminolink- spacer 18- GGT AGG TAA CCT ACC TCA GCT GCG (SEQ. ID. No. 14)
comp 12	CGC ACG CAA GGT TAC CTA CCC GAT (SEQ. ID. No. 15)
comp 14	CGC AGC TGA GGT AGG TTA CCT ACC (SEQ. ID. No. 16)

In the Claims:


Please cancel claims 1-119 and 138-147.

**REMARKS**

Pursuant to 37 CFR § 1.121, attached as Appendix A is a Version With Markings to Show Changes Made. In view of the all of the foregoing, applicants submit that this case is in condition for allowance and such allowance is earnestly solicited.

Respectfully submitted,

Date: September 26, 2001

  
Georgia Evans  
Registration No. 44,597

NIXON PEABODY LLP  
Clinton Square, P.O. Box 31051  
Rochester, New York 14603  
Telephone: (716) 263-1672  
Facsimile: (716) 263-1600

## Appendix A

### Version With Markings to Show Changes Made

In reference to the amendments made herein to the specification, additions appear as double-underlined text, as indicated below:

#### In The Specification:

At page 1, lines 4-5

This application is a divisional of U.S. Patent Application Serial No. 08/794,851, filed February 4, 1997, which claims the benefit of U.S. Provisional Patent Application Serial No. 60/011,359, filed February 9, 1996.

At page 17, lines 9-29:

Figure 6 is a flow diagram of a PCR/LDR process, in accordance with the present invention, where insertions (top left set of probes) and deletions (bottom right set of probes) are distinguished. On the left, the normal sequence contains 5 A's in a polyA tract. The mutant sequence has an additional 2As inserted into the tract. Therefore, the LDR products with addressable array-specific portions Z1 (representing the normal sequence) and Z3 (representing a 2 base pair insertion) would be fluorescently labeled by ligation to the common primer. While the LDR process (e.g., using a thermostable ligase enzyme) has no difficulty distinguishing single base insertions or deletions in mononucleotide repeats, allele-specific PCR is unable to distinguish such differences, because the 3' base remains the same for both alleles. On the right, the normal sequence is a (CA)<sub>5</sub> repeat (i.e. CACACACACA (SEQ. ID. No. 1)). The mutant contains two less CA bases than the normal sequence (i.e. CACACA). These would be detected as fluorescent LDR products at the addressable array-specific portions Z8 (representing the normal sequence) and Z6 (representing the 2 CA deletion) addresses. The resistance of various infectious agents to drugs can also be determined using the present invention. In Figure 6, the presence of ligated product sequences, as indicated by fluorescent label F, at the address having capture oligonucleotides complementary to Z1 and Z3 demonstrates the presence of both the normal and mutant poly A sequences. Similarly, the presence of ligated product sequences, as indicated by fluorescent label F, at the address having capture oligonucleotides complementary to Z6 and

Z8 demonstrates the presence of both the normal CA repeat and a sequence with one repeat unit deleted.

At page 40, lines 14-34:

To illustrate the concept, a subset of six of the 36 tetramer sequences were used to construct arrays: 1 = TGCG; 2 = ATCG; 3 = CAGC; 4 = GGTA; 5 = GACC; and 6 = ACCT. This unique set of tetramers can be used as design modules for the required 24-mer addressable array-specific portion and 24-mer complementary capture oligonucleotide address sequences. This embodiment involves synthesis of five addressable array-specific portion (sequences listed in Table 2). Note that the numbering scheme for tetramers allows abbreviation of each portion (referred to as "Zip #") as a string of six numbers (referred to as "zip code").

**Table 2. List of all 5 DNA/PNA oligonucleotide address sequences.**

Zip #	Zip code	Sequence (5' → 3' or NH <sub>2</sub> → COOH)	G+C
Zip11	1-4-3-6-6-1	TGCG-GGTA-CAGC-ACCT-ACCT-TGCG (SEQ. ID. No. 2)	15
Zip12	2-4-4-6-1-1	ATCG-GGTA-GGTA-ACCT-TGCG-TGCG (SEQ. ID. No. 3)	14
Zip13	3-4-5-6-2-1	CAGC-GGTA-GACC-ACCT-ATCG-TGCG (SEQ. ID. No. 4)	15
Zip14	4-4-6-6-3-1	GGTA-GGTA-ACCT-ACCT-CAGC-TGCG (SEQ. ID. No. 5)	14
Zip15	5-4-1-6-4-1	GACC-GGTA-TGCG-ACCT-GGTA-TGCG (SEQ. ID. No. 6)	15

Each of these oligomers contains a hexaethylene oxide linker arm on their 5' termini [P. Grossman, et al., Nucl. Acids Res., 22:4527-4534 (1994), which is hereby incorporated by reference], and ultimate amino-functions suitable for attachment onto the surfaces of glass slides, or alternative materials. Conjugation methods will depend on the free surface functional groups [Y. Zhang, et al., Nucleic Acids Res., 19:3929-3933 (1991) and Z. Guo, et al., Nucleic Acids Res., 34:5456-5465 (1994), which are hereby incorporated by reference].

At page 42, lines 17-25:

This concept is illustrated below using the two addresses, Zip 12 and Zip 14. These two addresses are the most related among the 25 addresses schematically represented in Figures 18 and 20 (discussed *infra*). These two addresses have in common tetramers on every alternating position (shown as underlined):

Zip 12 (2-4-4-6-1-1) = 24 mer

5' - ATCG GGTA GGTA ACCT TGCG TGCG-3' (SEQ. ID. No. 7)

Zip 14 (4-4-6-6-3-1) = 24 mer



5' - GGTA GGTA ACCT ACCT CAGC TGCG-3' (SEQ. ID. No. 8)

At page 42, lines 27-33:

In addition, they have in common a string of 12 nucleotides, as well as the last four in common (shown as underlined):

Zip 12 (2-4-4-6-1-1) = 24 mer

5' - ATCG GGTA GGTA ACCT TGCG TGCG-3' (SEQ. ID. No. 9)

Zip 14 (4-4-6-6-3-1) = 24 mer

5' - GGTA GGTA ACCT ACCT CAGC TGCG-3' (SEQ. ID. No. 10)

At page 43, lines 1-7:

Furthermore, for other capture oligonucleotides, such as Zip 3, the number of shared nucleotides is much lower (shown as underlined):

Zip 12 (2-4-4-6-1-1) = 24 mer

5' - ATCG GGTA GGTA ACCT TGCG TGCG-3' (SEQ. ID. No. 11)

Zip 3 (3-6-5-2-2-3) = 24 mer

5' - CAGC ACCT GACC ATCG ATCG CAGC-3' (SEQ. ID. No. 12)

At page 55, lines 9-24:

Typically, 10 pmol of each of the oligonucleotides comp 12 and comp 14 (see Table 3) were 5' end labeled in a volume of 20  $\mu$ l containing 10 units of T4 polynucleotide kinase (New England Biolabs, Beverly, MA), 2.22 MBq (60  $\mu$ Ci) [ $\gamma$ - $^{32}$ P] ATP, 50 mM Tris-HCl, pH 8, 10 mM MgCl<sub>2</sub>, 1 mM EDTA, and 10 mM dithiothreitol, according to a slightly modified standard procedure described in the literature. Unincorporated radioactive nucleotides were removed by filtration over a column containing superfine DNA grade Sephadex G-25 (Pharmacia, Piscataway, NJ). The Sephadex was preswollen overnight at 4 °C in 10 mM ammonium acetate. The labeled oligonucleotide probes were dried in vacuum and dissolved in hybridization solution (0.5 M Na<sub>2</sub>HPO<sub>4</sub> [pH 7.2], 1% crystalline grade BSA, 1 mM EDTA, 7% SDS). The specific activity of the labeled oligonucleotide probes comp 12 and comp 14 was  $2.86 \times 10^6$  cpm/pmol and  $2.43 \times 10^6$  cpm/pmol, respectively.

**Table 3. Oligonucleotides used (5' to 3')**

12	Aminolink- spacer 18- ATC GGG TAG GTA ACC TTG CGT GCG ( <u>SEQ. ID. No. 13</u> )
14	Aminolink- spacer 18- GGT AGG TAA CCT ACC TCA GCT GCG ( <u>SEQ. ID. No. 14</u> )
comp 12	CGC ACG CAA GGT TAC CTA CCC GAT ( <u>SEQ. ID. No. 15</u> )
comp 14	CGC AGC TGA GGT AGG TTA CCT ACC ( <u>SEQ. ID. No. 16</u> )